Jun 28 |
Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
|
Jun 28 |
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
|
Jun 28 |
Rocket falls as FDA rejects gene therapy Kresladi
|
Jun 28 |
Rocket gene therapy rejected by FDA over manufacturing
|
Jun 28 |
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
|
Jun 5 |
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
|
May 31 |
Rocket Pharmaceuticals (NASDAQ:RCKT) Is In A Good Position To Deliver On Growth Plans
|
May 30 |
EC grants orphan medicinal product status to Rocket’s RP-A601
|
May 29 |
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
|
May 12 |
Cantor picks 14 undervalued biotech stocks worth a second look
|